ADVENTRX Acquires Additional Oncology Drug Through Exclusive License Agreement
October 04 2005 - 9:30AM
Business Wire
ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) and privately held SD
Pharmaceuticals Inc. (SD Pharma) today announced SD Pharma's grant
to ADVENTRX of an exclusive license of certain rights to ANX-530, a
novel emulsion formulation of vinorelbine tartrate. In preclinical
testing, ANX-530 demonstrated markedly reduced vein irritation
following repeated IV injections compared with Navelbine(R),
GlaxoSmithKline's U.S. Food and Drug Administration (FDA)-approved
form of vinorelbine. Severe phlebitis is a known complication of
standard vinorelbine therapy. Vinorelbine is currently used as a
monotherapy or in combination with other chemotherapeutic agents
for the treatment of non-small-cell lung, breast, ovarian and other
cancers. ADVENTRX currently plans to pursue a 505(b)(2) regulatory
path for ANX-530 and has initiated discussions with the FDA for the
clinical trial design. The Company is preparing for its
pre-Investigational New Drug (IND) meeting with the FDA scheduled
for December 2005. Section 505(b)(2) of the U.S. Food, Drug &
Cosmetic Act allows the FDA to approve a follow-on drug on the
basis of data in the scientific literature or data used by the FDA
in the approval of other drugs. This procedure potentially makes it
easier for drug manufacturers to obtain rapid approval of new forms
of drugs based on proprietary data of the original drug
manufacturer. "We view the development of this novel formulation of
vinorelbine as a valuable improvement in a well-established cancer
therapy," said Brian M. Culley, vice president of business
development for ADVENTRX. "Furthermore, ANX-530 is an excellent fit
with our strategy to broaden our product pipeline and to
commercialize treatments that improve upon the safety and
performance of currently marketed therapies." "We recognized a
significant advantage in developing vinorelbine in a delivery
vehicle that prevents direct contact with cells lining the vein as
a means of reducing tissue damage at the injection site in patients
suffering from cancer," said Paul J. Marangos, Ph.D., chairman and
CEO of SD Pharma. "I am confident in ADVENTRX's ability to
efficiently advance this compound through the regulatory process."
Vinorelbine works by disrupting microtubule formation and is a
member of the class of antineoplastic drugs known as vinca
alkaloids, agents that inhibit cellular replication and ultimately
cause cellular death. Vinorelbine and other drugs in the vinca
alkaloid category are classified as vesicants and may cause severe
injection site reactions. Vinorelbine can cause both irritant and
vesicant types of injection site reactions. Irritants cause an
acute and limited irritation to the vein while vesicants cause an
injection site reaction. Studies have shown injection site
reactions, including erythema, pain at injection site, and vein
discoloration, occur in approximately one-third of non-small-cell
lung cancer (NSCLC) patients treated with vinorelbine. The license
agreement between ADVENTRX and SD Pharma grants ADVENTRX exclusive
U.S. rights to ANX-530 and all future intellectual property related
to vinca alkaloid formulations, including compositions for
delivering highly water-soluble drugs such as vinca alkaloids and
methods of using such compositions. According to the American
Cancer Society, approximately 80% of the more than 173,000
Americans diagnosed with lung cancer each year have NSCLC. Lung
cancer is the leading cause of cancer death and more than 160,000
people in the U.S. will die each year from the disease. Breast
cancer is the most common non-skin cancer and second leading cause
of cancer-related death in women with more than 200,000 new cases
diagnosed in the U.S. annually. Additionally, each year there are
more than 20,000 new cases of ovarian cancer diagnosed and more
than 16,000 deaths from the disease. About ADVENTRX ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development
company focused on introducing new technologies for anticancer and
antiviral treatments that improve the performance and safety of
existing drugs by addressing significant problems such as drug
metabolism, toxicity, bioavailability, and resistance. The
Company's lead compound, CoFactor, is a biomodulator of
5-fluorouracil (5-FU), a widely used cancer chemotherapy. CoFactor
is currently being tested with 5-FU in a U.S.-based Phase II and an
EU-based Phase IIb clinical trial as a first-line treatment of
metastatic colorectal cancer. In addition, CoFactor has received
clearance under a special protocol assessment from the FDA to begin
a Phase III pivotal clinical trial for metastatic colorectal
cancer. More information can be found on the Company's Web site at
www.adventrx.com. About SD Pharmaceuticals Inc. SD Pharmaceuticals
Inc. is a privately-held formulation innovation company that
targets approved drugs that display formulation-related safety and
efficacy constraints sufficient to warrant Black Box safety
warnings with the goal of improving these parameters through novel
reformulation technology. The Company has a portfolio of
patent-protected reformulated cancer and infectious disease drugs
that it believes can be developed utilizing the 505(b)2 regulatory
path. Further information can be found at www.sdpharma.com.
Forward-Looking Statements Regarding ADVENTRX This press release
contains forward-looking statements, within the meaning of the
"safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995, regarding ADVENTRX. Such statements are made
based on management's current expectations and beliefs. Actual
results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, the
validity of research results, and the receipt of necessary
approvals from the FDA and other regulatory agencies. For a
discussion of such risks and uncertainties, which could cause
actual results to differ from those contained in the
forward-looking statements regarding ADVENTRX, see the section
titled "Risk Factors" in ADVENTRX's last quarterly report on Form
10-Q, as well as other reports that ADVENTRX files from time to
time with the Securities and Exchange Commission. All
forward-looking statements regarding ADVENTRX are qualified in
their entirety by this cautionary statement. ADVENTRX undertakes no
obligation to release publicly any revisions, which may be made to
reflect events or circumstances after the date hereof.
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024